GSK welcomes Medicines Australia strategic agreement
09 May 2017
GlaxoSmithKline (GSK) Australia welcomes the Government’s commitment to the Medicines Australia strategic agreement.
"Healthy people contribute to a healthy community. Investing in new medicines is critical to improving the health of Australians," said Anne Belcher, general manager, GSK Pharmaceuticals.
"It takes a very long time to develop a medicine or vaccine. From research bench to bedside takes up to 15 years.
"The agreement between industry and governments as part of the Medicines Australia strategic agreement provides much needed predictability and stability," she added.
GSK is the largest supplier of vaccines to the Australian Government’s National Immunisation Program and a leader in respiratory medicines.
The Company employees 1250 people and has two manufacturing facilities in Australia. Pharmaceutical products are manufactured in Boronia on the outskirts of Melbourne. It is one of GSK’s largest sterile facilities globally, and includes two Relenza lines and innovative blow-fill-seal technology. The GSK site at Ermington, in north-western Sydney, manufactures consumer products such as Panadol.
Bernadette Murdoch, Communications Director Australasia, Phone: 0449 950 745